BACKGROUND: Although an increasing number of noninvasive fibrosis markers are available in HCV-monoinfected patients, data on the performance of these tests in HIV-HCV-coinfected patients are lacking.
OBJECTIVE:
To assess the diagnostic performance for predicting hepatic fibrosis stage of four simple and inexpensive noninvasive indexes (FIB-4, APRI, Forns, and platelet count) in HIV-HCV-coinfected patients.
METHODS:
Two hundred consecutive HIV-HCV-coinfected patients from the ANRS-CO3 Aquitaine cohort who underwent liver biopsy were studied. Fibrosis stage was assessed according to Metavir scoring system by a single pathologist unaware of the data of the patients. Diagnostic performances were assessed by measuring the areas under the receiver operating characteristic curves (AUROC) and the percentage of patients correctly identified (PCI).
RESULTS:
For predicting significant fibrosis (F ≥ 2), APRI, Forns index, and FIB-4 had AUROCS of 0.77, 0.75, and 0.79, with 39%, 25%, and 70% of PCI, respectively. For predicting severe fibrosis (F ≥ 3), FIB-4 had AUROC of 0.77 with 56% of PCI. For predicting cirrhosis (F4), FIB-4, APRI, and platelet count had AUROCs of 0.80, 0.79, and 0.78, with 59%, 60%, and 76% of PCI, respectively. Overall, diagnostic performances of the different indexes did not differ significantly for both significant fibrosis and cirrhosis.
INTRODUCTION

Chronic hepatitis C virus (HCV) infection is common in patients with human immunodeficiency virus (HIV) (1, 2).
Among the 40 million HIV-infected persons worldwide, an estimated 4-5 million are also chronically infected with HCV (1). HIV infection notably modifies the natural history of HCV infection with an accelerated progression of HCVrelated liver disease toward cirrhosis (3) (4) (5) (6) (7) . In addition, response to antiviral therapy in HIV-HCV-coinfected is poorer than in HCV-monoinfected patients with higher discontinuation rates (8) (9) (10) . Therefore, assessment of liver fibrosis is of critical importance in HIV-HCV-coinfected patients not only for prognosis but also for antiviral therapy indications. Until recently, liver biopsy was the only way to evaluate fibrosis (11) . However, liver biopsy is an invasive and painful procedure with rare but potentially life-threatening complications (12, 13) . Thus many patients are reluctant to undergo liver biopsies and HIV-HCV-coinfected patients may be discouraged to start anti-HCV treatment for this reason. The accuracy of liver biopsy to assess fibrosis has also been questioned in relation to sampling errors and intra-and inter-observer variability that may lead to over-or understaging (14) (15) (16) . These findings thus emphasize the need for accurate noninvasive methods to measure the degree of liver fibrosis. Several markers and models have been proposed over the past few years for the prediction of fibrosis in HCVmonoinfected patients, including the aspartate aminotransferase (AST) to platelet ratio index (17) , the Forns index (18) , and platelet count (19) . However, very little information regarding the performance and utility of these tests in HIV-HCV-coinfected patients is available. Finally, FIB-4, a new index based on age, alanine aminotransferase (ALT), AST, and platelets has been specifically designed for predicting severe liver fibrosis in HIV-HCV-co-infected patients (20) . Although this index has been very recently studied in HCV-monoinfected patients (21), it has not been validated independently in HIV-HCV-coinfected patients.
The aim of our study was to evaluate the diagnostic performance of APRI, Forns index, FIB-4, and platelet count for predicting liver fibrosis in HIV-HCV-coinfected patients.
PATIENTS AND METHODS
Patients
This retrospective study included patients with HIV-HCV coinfection who were referred for liver biopsy prior to HCV antiviral therapy at the University Hospital of Bordeaux between January 1999 and January 2005. Inclusion criteria were: age above 18, positive serum antibodies to HCV by means of a second-or third-generation HCV enzyme-linked immunosorbent assay (Ortho Diagnostic, Raritan, NJ) and detectable serum HCV RNA (Amplicor HCV, Roche Molecular Systems, Pleasanton, CA). Exclusion criteria were: coinfection with hepatitis B, other known causes of liver disease, and alcohol intake of more than 50 g/day. A total of 200 patients of the Aquitaine Cohort met those criteria.
The ANRS CO3 Aquitaine Cohort, a prospective hospitalbased cohort of HIV-1-infected patients under routine clinical management, was initiated in 1987 in the Bordeaux University Hospital and four other public hospitals in the Aquitaine region, Southwestern France, by the Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA) (22) . All adult patients with HIV-1 infection confirmed by Western-blot testing, and who have given an informed consent are enrolled in the cohort, whatever their clinical stage, gender or HIV transmission group. Additionally, information from at least one follow-up visit after the baseline assessment or known date of death has to be available. At each hospital contact, a standardized questionnaire including epidemiological, clinical, biological, and therapeutic data is filled in by clinicians and entered into the database. The schedule of follow-up visits is based on clinical practice, and an active search of patients lost to follow-up is performed annually.
Histological Assessment
The liver biopsy specimen was fixed in 10% formalin, paraffin-embedded, and serially sectioned. Sections were stained with hematoxylin-eosin-safran, Masson's trichrome, picrosirius red, and Gordon and Sweet's stains. Biopsy samples were read by a single experienced pathologist (BLB) who was unaware of the clinical data of the patients, using the Metavir scoring system for fibrosis (23) : F0 = no fibrosis; F1 = portal fibrosis without septa; F2 = portal fibrosis with rare septa; F3 = numerous septa without cirrhosis; F4 = cirrhosis.
Noninvasive Indexes for Prediction of Fibrosis
AST, ALT, gamma-GT, cholesterol, and platelet count, routinely determined for all patients, were available on the day of liver biopsy for 55% of patients, and within 1 month of the time of liver biopsy for 45%. APRI, Forns index, and FIB-4 were calculated using the formula originally described (17, 18, 20) . The cutoffs used were those proposed in the original studies. For platelet count, a cutoff of 150 10 9 /L (19) was used for predicting cirrhosis.
Statistical Analysis
Continuous variables were described by their mean and standard deviation (SD) or median and interquartile range (IQR) and categorical variables by percentages. To evaluate the diagnostic performance of the different indexes, sensitivity (Se), specificity (Spe), positive predictive value (PPV), and negative predictive value (NPV) were calculated, using cutoffs previously described for each index (17, 18, 20) . The overall diagnostic performance of scores was evaluated by area under the receiver operating characteristic curves (AU-ROC). The percentage of patients correctly identified (PCI) was also estimated for each index. AUROCs were compared according to the procedure proposed by Hanley and McNeil (24) . Statistical analyses were performed using Stata Statistical software, version 9.2 (Stata Corporation, College Station, TX).
RESULTS
Study Population
The main characteristics of the 200 HIV-HCV-coinfected patients included are presented in Table 1 . The mean age was 39.8 ± 6.3 years and 67% of patients were male. Their median CD4 cell count was 500 (78-1,644) cell/µL. Most patients (87%) were receiving highly active antiretroviral therapy (HAART) at the time of noninvasive evaluation of liver fibrosis. The mean platelet count did not differ between patients receiving HAART (N = 174) or not (N = 26): 191 ± 68 vs 171 ± 55 10 9 /L, respectively (P = NS). Significant fibrosis (F ≥ 2) was present in 157 patients (78.5%) and cirrhosis in 40 (20%). The mean liver biopsy length was 15.7 ± 7.5 mm. Biopsy length was greater than 10 mm in 154 patients (81%), and greater than 15 mm in 89 (46.8%) ( Table 2) . 30 . AST = aspartate aminotransferase; ALT = Alanine aminotransferease; ULN = upper limit of normal, PI = protease inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; NNRTI = nonnucleoside reverse transcriptase inhibitor.
Diagnostic Value of the Indexes
AUROCs were calculated to assess the overall diagnostic performance of each index for prediction of significant (F ≥ 2), severe fibrosis (F ≥ 3), and cirrhosis (F4) ( Table 2) .
AUROCs of Forns index, APRI, and FIB4 for discriminating F0F1 versus F2F3F4 were 0.75, 0.77, and 0.79, respectively. AUROC of FIB-4 for discriminating F0F1F2 versus F3F4 was 0.77. AUROCs of FIB4, APRI, and platelet count for discriminating F0F1F2F3 versus F4, were 0.80, 0.79, and 0.78, respectively.
Comparison of AUROC values of the different indexes did not show any statistically significant difference for both significant fibrosis and cirrhosis. Also, no difference was found according to liver biopsy length or between patients receiving HAART or not.
Indexes Aimed at Predicting Significant Fibrosis
For an FIB4 index ≤0.6, 9 of 43 patients (20.9%) without significant fibrosis at liver biopsy were correctly identified (Table 3 ). In addition, the presence of significant fibrosis could not be excluded as 3 out of 12 of patients with an FIB4 index ≤0.6 had significant fibrosis at liver biopsy (NPV = 75%). For an FIB4 ≥1, 131 of 157 patients (83.4%) with 
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significant fibrosis at liver biopsy were correctly identified. In addition, 131 of 151 patients with FIB4 ≥1 had significant fibrosis at liver biopsy (PPV = 86.7%).
For an APRI ≤0.5, 21 of 43 patients (48.8%) without significant fibrosis at liver biopsy were correctly identified (Table 3 ). In addition, the presence of significant fibrosis could not be excluded with certainty, as 19 of 40 patients with APRI ≤0.5 had significant fibrosis at liver biopsy (NPV = 52.5%). For an APRI ≥1.5, only 57 of 157 patients (36.3%) with significant fibrosis at liver biopsy were correctly identified. In addition, 57 of 59 patients with APRI ≥1.5 had significant fibrosis at liver biopsy (PPV = 96.6%).
For a Forns index <4.2, only 34.6% of patients without significant fibrosis at liver biopsy were correctly identified ( Table 3 ). The presence of significant fibrosis could not be excluded as 69% of patients with a Forns index <4.2 had significant fibrosis at liver biopsy (NPV = 31%). For a Forns index >6.9, only 23% of patients with significant fibrosis at liver biopsy were correctly identified. In addition, all the patients with a Forns index >6.9 had significant fibrosis at liver biopsy (PPV = 100%).
Overall, using FIB4, APRI, and Forns index, liver biopsy could have been avoided in 70%, 39%, and 25% of patients, respectively.
Index Aimed at Predicting Severe Fibrosis
For an FIB-4 ≤1.45, 90 of 129 patients (69.8%) without severe fibrosis at liver biopsy were correctly identified (Table 4) . 
Indexes Aimed at Predicting Cirrhosis
For an FIB4 ≤1.45, 102 of 160 patients (63.7%) without cirrhosis at liver biopsy were correctly identified (Table 5 ). In addition, the presence of cirrhosis could not be excluded totally, as 7 of 109 patients with an FIB4 ≤1.45 had cirrhosis at liver biopsy (NPV = 93.6%). For an FIB4 ≥ 3.25, 16 of 40 patients (40%) with cirrhosis at liver biopsy were correctly identified. In addition, 16 of 31 patients with an FIB4 ≥ 3.25 had cirrhosis at liver biopsy (PPV = 51.6%).
For an APRI ≤1, 100 of 160 patients (62.5%) without cirrhosis at liver biopsy were correctly identified (Table 5 ). In addition, the presence of cirrhosis could not be excluded totally, as 6 of 106 patients with an APRI ≤1 had cirrhosis at liver biopsy (NPV = 94.3%). For an APRI >2, 19 of 40 patients (47.5%) with cirrhosis at liver biopsy were correctly identified. In addition, 19 of 44 patients with an APRI >2 had cirrhosis at liver biopsy (PPV = 43.2%). Se = sensitivity; Spe = specificity; PPV = positive predictive value; NPV = negative predictive value = PCI = patients correctly identified; AUROC = area under the receiver operating characteristic curve. * : <cutoff means absence of cirrhosis and; >cutoff means presence of cirrhosis. † : <cutoff means presence of cirrhosis and > cutoff means absence of cirrhosis.
Platelet count <150.10 9 g/L, identified correctly 27 of 40 patients (67.5%) with cirrhosis at liver biopsy ( Table 5 ). The absence of cirrhosis could not be excluded totally as 13 of 137 (9.5%) patients with platelets count ≥150.10 9 g/L had cirrhosis at liver biopsy (NPV = 90.5%).
Overall, using FIB4, APRI, and platelet count, liver biopsy could have been avoided in 59%, 60%, and 76% of patients, respectively.
DISCUSSION
Although noninvasive markers of liver fibrosis are being increasingly used in clinical practice in HCV-monoinfected patients (25, 26) , data on the performance of these tests in HIV-HCV-coinfected patients are lacking. The Fibrotest (27) was one of the few tests evaluated in HIV-HCV coinfection. In a retrospective study in 130 patients (28) , the AUROC for detection of significant fibrosis (Metavir F ≥ 2) was 0.85. For a Fibrotest value <0.2, significant fibrosis could be excluded with 93% certainty (NPV 93%), whereas for a value >0.6, the presence of significant fibrosis could be predicted with 86% certainty (PPV 86%). Overall, liver biopsy could have been avoided in approximately 55% of patients. Recently, an index based on hyaluronic acid, albumin and AST (SHASTA) has been proposed in HIV-HCV-coinfected patients (29) . For a value <0.3, fibrosis could be excluded with 94% certainty (NPV 94%), whereas for a value >0.8 the presence of significant fibrosis could be predicted with 100% certainty. Overall, liver biopsy could have been avoided in approximately onethird of patients. It must be stressed, however, that Fibrotest and SHASTA are based on laboratory parameters not routinely performed and use a complex formula that limits their clinical applicability.
In the present study, we assessed the diagnostic performance of several simple and inexpensive noninvasive indexes based on routinely available laboratory tests (APRI, Forns index, FIB-4, and platelet count), for the prediction of liver fibrosis in HIV-HCV-coinfected patients. Liver biopsy was used as the reference for the diagnosis of fibrosis. We assessed the performance of different indexes by measuring AUROC curve. Overall, AUROC curves did not differ significantly between the indexes (Forns, APRI, FIB-4, or platelet count) for both significant fibrosis and cirrhosis. No difference was found according to liver biopsy length either. Finally, the diagnostic performance of these scores was lower in HIV-HCV-coinfected patients than that found in the original studies performed on HCV-monoinfected patients. For instance, the diagnostic accuracy of APRI and Forns index for significant fibrosis (with AUROCs of 0.77 and 0.75, respectively) was lower than that found in the original studies (17, 18) performed on HCV-monoinfected patients (in which the AUROCs were 0.88 and 0.81, respectively) but similar to the latest independent reports (19, 30, 31) . APRI predicted the presence of significant fibrosis with 96.6% certainty (only 3.4% of patients with a score ≥1.5 did not have significant fibrosis), and overall 39% of patients were correctly classified. Similarly, Forns index predicted the presence of significant fibrosis with 100% certainty. However, no more than 25% of patients could be correctly classified. Finally, liver biopsy could have been avoided in 39% and 25% of our patients using APRI and Forns index, respectively, as compared with around 50% in the original studies. These findings are in line with those of Macias et al. (32) in 263 HIV-HCV-coinfected patients in whom liver biopsy could have been avoided in only 1/3 of patients using APRI and Forns index for prediction of significant fibrosis.
One possible explanation for such a discrepancy between our findings and those from original studies could be the difference for the prevalence of significant fibrosis among studies: higher in our HIV-HCV-coinfected population (78.5%) than in the original studies, ranging from 26% to 50% (17, 18) . Also, performance of APRI and Forns index could be affected in HIV-HCV-coinfected patients by factors such as HAART-associated hepatotoxicity and HIV-induced thrombocytopenia (33) (34) (35) . However, in the present study, diagnostic performance (as measured by AUROCs) of Forns index and APRI as well as mean platelet count did not differ significantly between patients receiving HAART or not. On the contrary, FIB4 when used for the exclusion or the prediction of significant fibrosis (at cutoffs of 0.6 and 1, respectively) performed better than APRI and Forns index. These performances (AUROC 0.79 and 70% of PCI) are better than those published in the original study (AUROC 0.71 and 52% of PCI) (20) . We have no clear explanation for this discrepancy, except, as stated before, differences in the prevalence of significant fibrosis between the two studies. It should be stressed, however, that specificity was very poor (20.9% and 53.5% for cutoffs ≤0.6 and ≥1, respectively) making FIB-4 as well as APRI and Forns index currently not suitable for confident use in clinical practice in HIV-HCV-coinfected patients, especially for making treatment decision.
When APRI was used for the prediction of cirrhosis, its diagnostic performance was better than that observed for significant fibrosis. For instance, an APRI ≤1 could exclude cirrhosis with 94% certainty (NPV = 94.3%). Similarly, FIB4 ≤ 1.45 and platelet count when ≥150 × 10 9 /L could exclude cirrhosis with 94% (NPV = 93.6%) and 90% certainty (NPV = 90.5%). Although this may be important for reassuring patients, it is of little clinical use as these patients still need a liver biopsy for treatment decision. By contrast, APRI, FIB4, and platelet count did not confidently predict the presence of cirrhosis. For an APRI>2, an FIB4 ≥ 3.25, and a platelet <150 × 10 9 /L, the positive predictive values for cirrhosis were low (43.2%, 51.6%, and 42.9%, respectively), which indicated a need of liver biopsy to stage for half of the patients. Overall, 60%, 59%, and 76% of patients could be correctly classified with APRI, FIB4, and platelet count. These results are in agreement with those obtained in HIV-HCV coinfection (32) as well as in HCV monoinfection (19, 30) .
With regards to the prediction of severe fibrosis (F3-F4), the diagnostic performance of FIB-4 with an AUROC of 0.77 was close to that reported in the original study (20) . For instance, an FIB-4 ≤ 1.45 could exclude severe fibrosis with 82% certainty (NPV = 82.6%). Conversely, an FIB-4 ≥ 3.25 could predict the presence of severe fibrosis with 71% certainty (PPV = 71.0%). However, the percentage of patients in whom liver biopsy could have been avoided (56%) was lower than in the original study (71%) (20) . Also on a clinical standpoint, 19 patients with severe fibrosis on liver biopsy and an FIB-4 ≤ 1.45 would have been falsely reassured with the risk of inappropriate management. Such a misclassification rate remains too high for confident use of FIB-4 in clinical practice.
One way to increase diagnostic accuracy of noninvasive markers in HIV-HCV-coinfected patients might be to use sequential algorithms combining several markers as recently suggested in HCV-monoinfected patients (36) . Further studies are needed to validate these algorithms in HIV-HCVcoinfected patients.
In conclusion, the overall diagnostic performance of these indexes was lower in HIV-HCV-coinfected patients than originally reported in HCV monoinfected-patients. The use of FIB-4, APRI, or platelet count could avoid liver biopsy for the diagnosis of significant fibrosis, severe fibrosis, and cirrhosis in up to 56-76% of cases in HIV-HCV-coinfected patients. However, given the high percentage of misclassified patients, these indexes do not currently appear to be suitable for routine clinical use in HIV-HCV-coinfected patients. Further external validations in larger HIV-HCV-coinfected populations are still needed to optimize the use of these noninvasive methods in such patients.
APPENDIX
